登录 查看组织和合同定价。
选择尺寸
关于此项目
线性分子式:
Pt(NH3)2Cl2
化学文摘社编号:
分子量:
300.05
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
EC Number:
239-733-8
MDL number:
产品名称
顺氯氨铂, European Pharmacopoeia (EP) Reference Standard
InChI key
LXZZYRPGZAFOLE-UHFFFAOYSA-L
InChI
1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2
SMILES string
N.N.Cl[Pt]Cl
grade
pharmaceutical primary standard
API family
cisplatin
manufacturer/tradename
EDQM
mp
270 °C (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
正在寻找类似产品? 访问 产品对比指南
Application
本欧洲药典参考标准仅用于欧洲药典中明确规定的用途。不保证适用于任何其他用途，用户请自行负责。本标准品不适用于人类或动物使用。
根据欧洲药典，用于配制下列给定溶液：
根据欧洲药典，用于配制下列给定溶液：
- 鉴定参考溶液，根据各论 0559，采用红外吸收光谱法和薄层色谱法检测相关物质，使用采用液相色谱法（通则 2.2.29）检测顺铂
- 参考溶液 (b)，根据各论 1081，使用液相色谱法（通则 2.2.29）检测异麦芽酮糖醇中的相关物质
Biochem/physiol Actions
强效的铂基抗肿瘤剂。与 DNA 二核苷酸 d(pGpG) 形成细胞毒性加合物，诱导链内交联。
General description
Other Notes
相应销售限制条件可能适用。
Packaging
本品按照现行药典要求提供。有关当前单位数量，请见EDQM 参考目录。
signalword
Danger
Hazard Classifications
Acute Tox. 2 Oral - Carc. 1B - Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
target_organs
Respiratory system
存储类别
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Carboplatin
European Pharmacopoeia Commission and European Directorate for the Quality of Medicines & Healthcare
European pharmacopoeia, 6104-6105 (2022)
Cisplatin
European Pharmacopoeia Commission and European Directorate for the Quality of Medicines & Healthcare
European pharmacopoeia, 2231-2232 (2009)
Michael F Milosevic et al.
International journal of cancer, 135(7), 1692-1699 (2013-08-02)
Radiotherapy (RT) with concurrent cisplatin (CRT) is standard treatment for locally advanced cervical cancer. However, not all patients benefit from the addition of cisplatin to RT alone. This study explored the value of pretreatment tumor interstitial fluid pressure (IFP) and
Yi-Long Wu et al.
The Lancet. Oncology, 14(8), 777-786 (2013-06-21)
The results of FASTACT, a randomised, placebo-controlled, phase 2 study, showed that intercalated chemotherapy and erlotinib significantly prolonged progression-free survival (PFS) in patients with advanced non-small-cell lung cancer. We undertook FASTACT-2, a phase 3 study in a similar patient population.
James Chih-Hsin Yang et al.
The Lancet. Oncology, 16(2), 141-151 (2015-01-16)
We aimed to assess the effect of afatinib on overall survival of patients with EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open-label, randomised, phase 3 trials. Previously untreated patients with EGFR mutation-positive stage IIIB or IV
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持